Table 4.
Pre-test probability of bone density below treatment T-score cutpoint and corresponding threshold weights for screen and treat strategy to be cost-effective for men without prior clinical fracture (societal WTP=$75,000 per QALY gained)
| Age (years) | Mean weight (kg)a | Prevalence BMD below Rx cutpoint (%)b | Drug cost $500 per year | Drug cost $250 year | ||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Cost-effective pre-test probability (%)c | Threshold weight (kg)d | Cost-effective pre-test probability (%) | Threshold weight (kg) | |||
| 55 | 91.0 | 2.03 | 15.2 | 67.2 | 7.14 | 76.5 |
| 60 | 92.7 | 2.77 | 7.87 | 80.6 | 4.87 | 86.2 |
| 65 | 90.5 | 4.65 | 4.46 | 91.0 | 3.40 | 94.4 |
| 70 | 88.7 | 7.23 | 2.68 | 101.2 | 2.24 | 103.4 |
| 75 | 86.9 | 8.38 | 2.44 | 102.5 | 1.65 | 107.3 |
| 80 | 81.6 | 10.74 | 1.30 | 108.3 | 1.19 | 109.4 |
a
Mean for US age-matched and sex-matched Caucasians (from NHANES 2005–2006 [20])
b
Prevalence of BMD below femoral neck T-score treatment cutpoint
c
Pre-test probability of low BMD warranting drug therapy at which bone densitometry is cost-effective
d
Body weight threshold corresponding to cost-effective pre-test probability of low BMD warranting drug therapy